$21.91
3.50% yesterday
Nasdaq, Nov 28, 04:19 pm CET
ISIN
US26817R1086
Symbol
DYN

Dyne Therapeutics Inc Stock price

$21.17
-3.00 12.41% 1M
+9.48 81.10% 6M
-2.39 10.14% YTD
-8.06 27.57% 1Y
+10.52 98.78% 3Y
+1.56 7.96% 5Y
-2.73 11.42% 10Y
-2.73 11.42% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.37 1.78%
ISIN
US26817R1086
Symbol
DYN
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.3b
Net debt
positive
Cash
$791.9m
Shares outstanding
142.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
91.1%
Return on Equity
-50.4%
ROCE
-55.6%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-447.2m | $-445.6m
EBIT
$-449.2m | $-480.5m
Net Income
$-423.8m | $-527.6m
Free Cash Flow
$-397.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-42.9% | -30.2%
EBIT
-42.8% | -39.7%
Net Income
-43.9% | -66.2%
Free Cash Flow
-62.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-2.8
Short interest
13.4%
Employees
206
Rev per Employee
$0.0
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Dyne Therapeutics Inc forecast:

17x Buy
81%
4x Hold
19%

Analyst Opinions

21 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
81%
Hold
19%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 64 64
15% 15%
-
- Research and Development Expense 385 385
49% 49%
-
-447 -447
43% 43%
-
- Depreciation and Amortization 1.98 1.98
21% 21%
-
EBIT (Operating Income) EBIT -449 -449
43% 43%
-
Net Profit -424 -424
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Positive
The Motley Fool
7 days ago
It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind.
Neutral
GlobeNewsWire
23 days ago
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 -
Neutral
GlobeNewsWire
25 days ago
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 206
Founded 2017
Website dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today